Biogen's (NASDAQ: BIIB) earnings report last week offered us a clear picture of why the biotech company is in need of a change. CEO Michel Vounatsos says the company is in the process of becoming not just an MS company -- but a full neuroscience company. Biogen recently reported positive data from a pivotal phase 3 trial investigating zuranolone for major depressive disorder (also known as clinical depression).
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting